Philip Ashton-Rickardt - Feb 18, 2022 Form 4 Insider Report for Sigilon Therapeutics, Inc. (SGTX)

Role
CHIEF SCIENTIFIC OFFICER
Signature
/s/ Matthew Kowalsky, Attorney-in-Fact
Stock symbol
SGTX
Transactions as of
Feb 18, 2022
Transactions value $
$133,200
Form type
4
Date filed
2/22/2022, 04:01 PM
Previous filing
Jan 4, 2022
Next filing
Mar 1, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGTX Stock Option (Right to Buy) Award $133K +90K $1.48 90K Feb 18, 2022 Common Stock 90K $1.48 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 25% of the underlying shares of common stock on February 18, 2023, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.